about
The Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsHepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesMutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumoursPeto's Paradox: evolution's prescription for cancer preventionAnimal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 YearsIntegrating mutation and gene expression cross-sectional data to infer cancer progression.Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activityIdentifying cancer type specific oncogenes and tumor suppressors using limited size data.von Willebrand factor type D domain mutant of SVS-1/SUSD2, vWD(m), induces apoptosis in HeLa cells.Recurrent hemizygous deletions in cancers may optimize proliferative potentialCTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancerFunctional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma modelHemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis.A strategy to identify dominant point mutant modifiers of a quantitative trait.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes.Selection for the G4 DNA motif at the 5' end of human genesFrequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma.Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy.VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancerDependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression.The utility of Apc-mutant rats in modeling human colon cancer.Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1A continuum model for tumour suppression.Proline oxidase functions as a mitochondrial tumor suppressor in human cancers.MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencingSomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms.Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system.Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling.Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian GenomicsThe Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer.Somatic Mutation Patterns in Hemizygous Genomic Regions Unveil Purifying Selection during Tumor EvolutionAssociation of PTEN gene polymorphisms with liver cancer risk.Molecular biology of gynecological cancer.The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.The role of Janus kinases in haemopoiesis and haematological malignancy.Reducing the genotoxic potential of retroviral vectors.
P2860
Q26772237-785D28A8-2A3A-4671-9E95-3D90FEA5548AQ26772317-8937B7AC-2E1E-4B4E-9DB9-E4DE85E2B377Q28281731-EDA23F61-CD33-4E2F-8D04-55C7CFFCEC8FQ28741797-45D48ED4-0F9E-4422-A118-5DA282F2DC48Q28829867-507F5FB4-0779-4A87-B599-7135A609B186Q31039903-E6100E5F-0F83-455E-BB0B-007F952C8E63Q31044138-4C35CD34-F930-4754-9535-210EC3ED267CQ31135256-44CCAD75-3884-42DD-819E-F29427ABD251Q33281816-1DAF02D8-61FE-4161-940F-3DB588E5BDB4Q33637152-6817510D-0A3E-466A-8F53-D71ABC5C3A38Q33692429-78427267-3661-4CA9-A20C-DAA482910CFFQ33693027-2ADC486D-148E-4A11-96EF-81363A7BC16BQ33711869-EC3E32E2-1B1A-4B70-BFA0-3587C8DA9B31Q33784960-49EFBD41-3649-4823-94E0-FFD0DCAAFFDCQ33823065-B587EB12-61C3-4B11-892C-FA1765BDF76CQ33858472-10F227CC-9DF0-4317-929A-A35E585B6DF3Q33884294-D24D45A5-D2B2-45FA-A461-20F4343879DCQ34139499-5116168F-7592-482C-A8E2-99E1B498695AQ34208511-78845494-FD63-425D-B56B-9A301B4C22BDQ34245117-DF01D2C4-FE7C-4741-9677-B6E6B45CD72BQ34328133-11C9EBE5-EFE6-46CA-8513-8E4696EB7CBDQ34351731-D1E1EBEB-CD6A-4274-ACBA-48ECE2A6AC61Q34424145-1C2D00E2-495D-453E-B7FF-73CFDF7FEEFBQ34572977-CCFE091C-04CD-4E36-84F8-E44716A39F77Q34631552-4BC3E01E-CE89-4EFE-AE2A-4A17394DC26BQ34872984-C9EBE127-E8A1-4D2B-9BE5-22D8F853D32BQ34992987-2E3797A4-5E62-4A26-AD11-0EF99703EA75Q35167227-D3E70A2E-B026-4BE5-BB4A-798E18620073Q35612083-B149358C-0BC1-44CE-BBD0-82F99409C8EDQ35750900-D6926EF8-1FF8-46D1-8DF1-5D838A362917Q35789615-D8363D01-6823-4720-8D0B-6BE84FDFA846Q35792269-43C81DDF-7171-4945-925B-555FC7E8EC2EQ35832872-093B1A8F-7BE0-4500-A52A-9C8FD0EFDA5CQ36095604-F77AAA31-C95E-4101-B23F-4256B6BDEBF4Q36233887-0A377D5B-6B4C-4F1C-AF2F-93E2CF203358Q36464903-0CEA6347-6D26-4974-9105-8704514BEC28Q36502779-5B1C1D8E-68C3-4395-BD11-12759AE2AE5FQ36508924-C70BB1BF-7924-42E7-A0C2-B0F154F60369Q36527760-AB233049-0585-46B3-9B4F-594B3DC7352BQ36670724-F356C737-2012-4DCA-9FC7-BF092F63B5D0
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tumor suppressor genetics.
@ast
Tumor suppressor genetics.
@en
type
label
Tumor suppressor genetics.
@ast
Tumor suppressor genetics.
@en
prefLabel
Tumor suppressor genetics.
@ast
Tumor suppressor genetics.
@en
P2860
P356
P1433
P1476
Tumor suppressor genetics.
@en
P2093
Christopher J Kemp
Shannon R Payne
P2860
P304
P356
10.1093/CARCIN/BGI223
P407
P577
2005-09-08T00:00:00Z